The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Signal transduction of the CB1 cannabinoid receptor
Open accessAbstract
The CB 1 cannabinoid receptor (CB 1 R) is the major cannabinoid receptor in neuronal cells and the brain, but it also occurs in endocrine cells and other peripheral tissues. CB 1 R is a member of the superfamily of G-protein-coupled receptors (GPCRs), which are characterized by seven transmembrane helices. The major mediators of CB 1 R are the G proteins of the G i/o family, which inhibit adenylyl cyclases in most tissues and cells, and regulate ion channels, including calcium and potassium ion channels. Regulation of ion channels is an important component of neurotransmission modulation by endogenous cannabinoid compounds released in response to depolarization and Ca 2+-mobilizing hormones. However, evidence exists that CB 1 Rs can also stimulate adenylyl cyclase via G s, induce receptor-mediated Ca 2+ fluxes and stimulate phospholipases in some experimental models. Stimulation of CB 1 R also leads to phosphorylation and activation of mitogen-activated protein kinases (MAPK), such as p42/p44 MAPK, p38 MAPK and c-Jun N-terminal kinase, which can regulate nuclear transcription factors. Activated and phosphorylated CB 1 Rs also associate with β-arrestin molecules, which can induce the formation of signalling complexes and participate in the regulation of GPCR signalling. Recent data also suggest that CB 1 Rs can form homo- and heterodimers/oligomers, and the altered pharmacological properties of these receptor complexes may explain the pharmacological differences observed in various tissues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Biochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 1×
“Molecular biological studies have identified two major cannabinoid receptors, the CB1 receptor (CB1R) and CB2 receptor (CB2R; Matsuda et al. 1990, Munro et al. 1993).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Determination and characterization of a cannabinoid receptor in rat brain
Devane, W. A., Dysarz, F. A., Johnson, M. R., Melvin, L. S., & Howlett, A. C. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09876-1 · Cited by 2,443 · cited 1×
“Although the lipophylic nature of cannabinoids slowed down the progress of pharmacological identification of its biological target, high-affinity-binding sites for cannabinoids in brain membranes were first reported in 1988 (Devane et al. 1988).”
BackgroundIsolation, Structure, and Partial Synthesis of an Active Constituent of Hashish
Gaoni, Y., & Mechoulam, R. (1964) · Journal of the American Chemical Society · doi:10.1021/ja01062a046 · Cited by 2,393
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 4×
“…including obesity and metabolic syndrome, mood and anxiety disorders, movement disorders, neuropathic pain, multiple sclerosis and spinal cord injury, as well as in atherosclerosis, myocardial infarction, stroke, hypertension, cancer, glaucoma and osteoporosis (Pacher et al. 2006, Table 1).”
BackgroundInfluentialThe orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · cited 2×
“Another report showed, using GTPgS binding in HEK293 cells, that GPR55 was activated by CP 55 940, O-1602, THC, palmitoylethanolamide, anandamide, 2-AG, cannabinoidal (abnormal-CBD) and virodhamine, and was coupled to G13 protein, without activation of Ca signal generation (Ryberg et al. 2007).”
BackgroundKatona, I., Sperlágh, B., Sı́k, A., Käfalvi, A., Vizi, E. S., Mackie, K., & Freund, T. F. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-11-04544.1999 · Cited by 1,218 · cited 1×
“Some other data suggest that the constitutive activity is not present in all CB1R expressing cells, or it can be inhibited by Ca 2C chelation (Katona et al. 1999, Hoffman & Lupica 2000, Wilson & Nicoll 2001, Chevaleyre & Castillo 2003, Savinainen et al. 2003, Breivogel et al. 2004, Hentges et al.…”
BackgroundBisogno, T., Howell, F., Williams, G., Minassi, A., Cascio, M. G., Ligresti, A., Matias, I., Schiano-Moriello, A., Paul, P., Williams, E.-J., et al. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200305129 · Cited by 1,039
GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current
Lauckner, J. E., Jensen, J. B., Chen, H.-Y., Lu, H.-C., Hille, B., & Mackie, K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711278105 · Cited by 712
Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.
Mackie, K., & Hille, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.3825 · Cited by 694
Seifert, R., & Wenzel-Seifert, K. (2002) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-002-0588-0 · Cited by 637
Mackie, K., Lai, Y., Westenbroek, R., & Mitchell, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06552.1995 · Cited by 626
Felder, C. C., Briley, E. M., Axelrod, J., Simpson, J. T., Mackie, K., & Devane, W. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.16.7656 · Cited by 475
Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs.
Howlett, A. C., Qualy, J. M., & Khachatrian, L. L. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10219-8 · Cited by 469
Bouaboula, M., Perrachon, S., Milligan, L., Canat, X., Rinaldi-Carmona, M., Portier, M., Barth, F., Calandra, B., Pecceu, F., Lupker, J., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22330 · Cited by 461
Identification of GPR55 as a lysophosphatidylinositol receptor
Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., & Sugiura, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.078 · Cited by 459
Bulenger, S., Marullo, S., & Bouvier, M. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.004 · Cited by 448
Naunyn-Schmiedeberg's archives of pharmacology: European Journal of Physiology
(1975) · Klinische Wochenschrift · doi:10.1007/bf01482719 · Cited by 446
Allosteric interactions between GB1 andGB2 subunits are required for optimalGABAB receptor function
Galvez, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.9.2152 · Cited by 383
Howlett, A. C., & Fleming, R. M. (1984) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)15066-9 · Cited by 375
Mackie, K., Devane, W. A., & Hille, B. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13215-x · Cited by 362
Kearn, C. S., Blake-Palmer, K., Daniel, E., Mackie, K., & Glass, M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.006882 · Cited by 359
In silico patent searching reveals a new cannabinoid receptor
Baker, D., Pryce, G., Davies, W. L., & Hiley, C. R. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.003 · Cited by 348
Functional CB1 cannabinoid receptors in human vascular endothelial cells
Liu, J., Gao, B., Mirshahi, F., Sanyal, A. J., Khanolkar, A. D., Makriyannis, A., & Kunos, G. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460835 · Cited by 333
Regulation of Extracellular Signal-Regulated Kinase by Cannabinoids in Hippocampus
Derkinderen, P., Valjent, E., Toutant, M., Corvol, J.-C., Enslen, H., Ledent, C., Trzaskos, J., Caboche, J., & Girault, J.-A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-06-02371.2003 · Cited by 331
The enigmatic pharmacology of GPR55
Ross, R. A. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.12.004 · Cited by 296
Detection of heteromerization of more than two proteins by sequential BRET-FRET
Carriba, P., Navarro, G., Ciruela, F., Ferré, S., Casadó, V., Agnati, L., Cortés, A., Mallol, J., Fuxe, K., Canela, E. I., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1229 · Cited by 283
Caulfield, M. P., & Brown, D. A. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb14321.x · Cited by 278
Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship?
Kenakin, T. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.040352 · Cited by 270
McPartland, J. M., Glass, M., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707399 · Cited by 266
Distinct Domains of the CB1 Cannabinoid Receptor Mediate Desensitization and Internalization
Jin, W., Brown, S., Roche, J. P., Hsieh, C., Celver, J. P., Kovoor, A., Chavkin, C., & Mackie, K. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-10-03773.1999 · Cited by 261
Howlett, A. C. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12377-8 · Cited by 255
Johns, D. G., Behm, D. J., Walker, D. J., Ao, Z., Shapland, E. M., Daniels, D. A., Riddick, M., Dowell, S., Staton, P. C., Green, P., et al. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707419 · Cited by 242
Ellis, J., Pediani, J. D., Canals, M., Milasta, S., & Milligan, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602494200 · Cited by 225
Dual Effects of Anandamide on NMDA Receptor‐Mediated Responses and Neurotransmission
Hampson, A. J., Bornheim, L. M., Scanziani, M., Yost, C. S., Gray, A. T., Hansen, B. M., Leonoudakis, D. J., & Bickler, P. E. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70020671.x · Cited by 208
Regional Differences in Cannabinoid Receptor/G-protein Coupling in Rat Brain
Breivogel, C. S., Sim, L. J., & Childers, S. R. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36967-8 · Cited by 202
The CB1 Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase
Rueda, D., Galve-Roperh, I., Haro, A., & Guzmán, M. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23114-x · Cited by 200
Guo, J., & Ikeda, S. R. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.665 · Cited by 190
Henry, D. J., & Chavkin, C. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11289-9 · Cited by 173
Hojo, M., Sudo, Y., Ando, Y., Minami, K., Takada, M., Matsubara, T., Kanaide, M., Taniyama, K., Sumikawa, K., & Uezono, Y. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08244fp · Cited by 173
Brown, S. P., Safo, P. K., & Regehr, W. G. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0918-04.2004 · Cited by 166
Marcellino, D., Carriba, P., Filip, M., Borgkvist, A., Frankowska, M., Bellido, I., Tanganelli, S., Müller, C. E., Fisone, G., Lluis, C., et al. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.011 · Cited by 164
Allosteric modulation of heterodimeric G-protein-coupled receptors
Milligan, G., & Smith, N. J. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.11.001 · Cited by 162
McAllister, S. D., Griffin, G., Satin, L. S., & Abood, M. E. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35147-x · Cited by 160
Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes
Rhee, M., Bayewitch, M., Avidor‐Reiss, T., Levy, R., & Vogel, Z. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71041525.x · Cited by 159 · cited 2×
“Coexpression of isoforms 2, 4 or 7 of adenylyl cyclase also resulted in CB1R-mediated stimulation of cAMP formation, but this effect was probably mediated by Gbg dimers released from Gi proteins (Rhee et al. 1998).”
BackgroundCannabinoids activate p38 mitogen‐activated protein kinases through CB1 receptors in hippocampus
Derkinderen, P., Ledent, C., Parmentier, M., & Girault, J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00333.x · Cited by 159
Hentges, S. T., Low, M. J., & Williams, J. T. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2769-05.2005 · Cited by 143
Sarnataro, D., Pisanti, S., Santoro, A., Gazzerro, P., Malfitano, A. M., Laezza, C., & Bifulco, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025601 · Cited by 143
Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?
Kunos, G., Osei‐Hyiaman, D., Bátkai, S., Sharkey, K. A., & Makriyannis, A. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.001 · Cited by 141
Davis, M. I., Ronesi, J. A., & Lovinger, D. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305697200 · Cited by 125
Paradisi, A., Pasquariello, N., Barcaroli, D., & Maccarrone, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707964200 · Cited by 121
Breivogel, C. S., & Childers, S. R. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38906-2 · Cited by 106
Adan, R. A. H., & Kas, M. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00130-5 · Cited by 101
Mukhopadhyay, S., McIntosh, H. H., Houston, D. B., & Howlett, A. C. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26454-3 · Cited by 101
Rinaldi, M. L., Duigou, A. L., Oustric, D., Barth, F., Bouaboula, M., Carayon, P., Casellas, P., & Fur, G. L. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37898-x · Cited by 98
Kouznetsova, M., Kelley, B. G., Shen, M., & Thayer, S. A. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12110-4 · Cited by 94
Nie, J., & Lewis, D. L. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-22-08758.2001 · Cited by 88
Graham, E. S., Ball, N., Scotter, E. L., Narayan, P. J., Dragunow, M., & Glass, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602516200 · Cited by 70
Azad, S. C., Kurz, J., Marsicano, G., Lutz, B., Zieglgänsberger, W., & Rammes, G. (2008) · Learning & Memory · doi:10.1101/lm.741908 · Cited by 68
Gardner, A. J., & Mallet, P. E. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.11.032 · Cited by 66
Differential Receptor–G-Protein Coupling Evoked by Dissimilar Cannabinoid Receptor Agonists
Houston, D. B., & Howlett, A. C. (1998) · Cellular Signalling · doi:10.1016/s0898-6568(98)00013-8 · Cited by 62
Rubovitch, V., Gafni, M., & Sarne, Y. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00174-2 · Cited by 60
Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases
Bellocchio, L., MANCINI, G., Vicennati, V., Pasquali, R., & Pagotto, U. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.09.001 · Cited by 53
Cannabinoids Modulate the P-Type High-Voltage-Activated Calcium Currents in Purkinje Neurons
Fisyunov, A., Tsintsadze, V., Min, R., Burnashev, N., & Lozovaya, N. (2006) · Journal of Neurophysiology · doi:10.1152/jn.01227.2005 · Cited by 50
Endoh, T. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706623 · Cited by 38
Korzh, A., Keren, O., Gafni, M., Bar-Josef, H., & Sarne, Y. (2008) · Brain Research · doi:10.1016/j.brainres.2007.10.070 · Cited by 33
Downer, E. J., Gowran, A., & Campbell, V. A. (2007) · Brain Research · doi:10.1016/j.brainres.2007.07.076 · Cited by 29
Steinberg, B. A., & Cannon, C. P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.10.011 · Cited by 26
Cited by
Fuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
Zou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,343
Plant derived substances with anti-cancer activity: from folklore to practice
Fridlender, M., Kapulnik, Y., & Koltai, H. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00799 · Cited by 415
CB 1 and CB 2 Receptor Pharmacology
Howlett, A. C., & Abood, M. E. (2017) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.03.007 · Cited by 375
Iannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
Metadata
- Authors
- Turu, G., & Hunyady, L.
- Venue
- Journal of Molecular Endocrinology
- Publisher
- Bioscientifica
- Published
- 2009-07-20
- Volume
- 44
- Issue
- 2
- Pages
- 75-85
- ISSN
- 0952-5041 (ISSN-L)
- 1479-6813
- OpenAlex
- W2089056164
- Cited by
- 325
- References
- 70
- FWCI
- 10.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.